Contracts › 75N93026C00012
75N93026C00012: To Develop a Therapeutic Small Molecule Viral Entry Inhibitor As a Medical Countermeasure for Filovirus Infection.
Awarded to Arisan Therapeutics Inc by National Institutes of Health (NIH).
$2.9Mobligated
$23.9Mpotential value
30 June 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93026C00012 |
|---|---|
| Awardee | Arisan Therapeutics Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | CA |
| Offers received | 20 |
| Period of performance | 03 August 2026 to 30 June 2027 |
| Potential end | 30 June 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record